| Nome |
# |
|
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients, file e4233f18-8511-2860-e053-6605fe0a460a
|
777
|
|
Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study, file e4233f18-7b1f-2860-e053-6605fe0a460a
|
502
|
|
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression, file 114fed17-b83b-46da-91ef-667cebee5d84
|
308
|
|
null, file e4233f17-03df-2860-e053-6605fe0a460a
|
84
|
|
High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study, file af98305d-13fa-42b5-8bd6-2e3e7fe2bd8b
|
27
|
|
Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts, file e4233f16-3962-2860-e053-6605fe0a460a
|
24
|
|
Phenotypic and proteomic analysis identifies hallmarks of blood circulating extracellular vesicles in NSCLC responders to immune checkpoint inhibitors, file e4233f18-50d2-2860-e053-6605fe0a460a
|
23
|
|
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells, file e4233f16-ec7e-2860-e053-6605fe0a460a
|
22
|
|
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable, file e4233f17-0908-2860-e053-6605fe0a460a
|
22
|
|
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results, file e4233f17-949c-2860-e053-6605fe0a460a
|
22
|
|
Predictive Ability for Disease-Free Survival of the GRade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell Carcinoma, file e4233f17-d007-2860-e053-6605fe0a460a
|
22
|
|
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: An insight from clinical practice, file e4233f17-8f85-2860-e053-6605fe0a460a
|
21
|
|
Axitinib after Sunitinib in metastatic renal cancer: Preliminary results from Italian "Real-World" SAX Study, file e4233f17-9589-2860-e053-6605fe0a460a
|
21
|
|
Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer, file 750a3119-9409-45aa-b0c4-77c77b7408be
|
20
|
|
Epidermal Growth Factor Immunotherapy: Exploring the Effects of NB-UVB Exposure, file e4233f18-556b-2860-e053-6605fe0a460a
|
20
|
|
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report, file e4233f16-2fa4-2860-e053-6605fe0a460a
|
19
|
|
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials, file e4233f17-03db-2860-e053-6605fe0a460a
|
19
|
|
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status, file e4233f16-27f8-2860-e053-6605fe0a460a
|
17
|
|
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study, file e4233f17-747f-2860-e053-6605fe0a460a
|
17
|
|
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation", file e4233f17-9200-2860-e053-6605fe0a460a
|
17
|
|
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A “snapshot” from clinical practice, file e4233f18-a98b-2860-e053-6605fe0a460a
|
17
|
|
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study, file e4233f16-7764-2860-e053-6605fe0a460a
|
16
|
|
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study, file e4233f17-962b-2860-e053-6605fe0a460a
|
16
|
|
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study, file e4233f17-dab5-2860-e053-6605fe0a460a
|
15
|
|
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study, file e4233f16-d1b8-2860-e053-6605fe0a460a
|
14
|
|
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: A multicenter study with external validation, file e4233f18-6120-2860-e053-6605fe0a460a
|
14
|
|
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice, file e4233f18-d023-2860-e053-6605fe0a460a
|
14
|
|
Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study, file e4233f18-83dd-2860-e053-6605fe0a460a
|
13
|
|
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression, file e4233f18-940d-2860-e053-6605fe0a460a
|
13
|
|
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey, file e4233f15-caa2-2860-e053-6605fe0a460a
|
12
|
|
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial, file e4233f16-27ed-2860-e053-6605fe0a460a
|
12
|
|
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study, file e4233f17-9612-2860-e053-6605fe0a460a
|
12
|
|
null, file e4233f16-fcb8-2860-e053-6605fe0a460a
|
11
|
|
Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study, file e4233f18-709f-2860-e053-6605fe0a460a
|
11
|
|
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score, file e4233f18-d188-2860-e053-6605fe0a460a
|
11
|
|
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study, file 3a4b6c7c-5bce-4ec1-8fd7-7ffb4638d71b
|
10
|
|
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status, file ddf3874d-0c99-4d51-acd6-3482728efa57
|
10
|
|
Deep polychromatic flow cytometry characterization of circulating endothelial cells in metastatic colorectal cancer patients, file e4233f18-978d-2860-e053-6605fe0a460a
|
10
|
|
Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer, file e671c42f-90e1-4bbe-9e73-05250e4c5bcb
|
10
|
|
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting, file eefa9c0c-0a62-48a3-b14b-64ceadad9992
|
10
|
|
Real world treatment practice in patients with advanced melanoma in the nivolumab era: five novel Italian case reports and a literature review, file e4233f17-038d-2860-e053-6605fe0a460a
|
9
|
|
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer, file e4233f15-0a20-2860-e053-6605fe0a460a
|
8
|
|
Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: A systematic review, file e4233f15-babe-2860-e053-6605fe0a460a
|
8
|
|
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study, file 36207e4f-6d04-477b-93ad-5ed1b9859ba9
|
7
|
|
Alectinib induced regression of renal and hepatic cysts caused by crizotinib, file 5e173c4c-077d-4a35-a612-8319748f2396
|
7
|
|
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting, file 26826aa7-b457-45c4-ad25-a9a93cb38bfd
|
6
|
|
Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort Study, file d2f341d2-5444-4d9e-9372-a2e01f884229
|
6
|
|
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study, file e1ff7b2d-1860-468c-8836-4204ca7fdc7f
|
6
|
|
Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study, file e4233f16-051b-2860-e053-6605fe0a460a
|
6
|
|
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer, file e4233f14-f164-2860-e053-6605fe0a460a
|
5
|
|
Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study, file 972a097b-901d-46d9-a1bc-34262902c52e
|
4
|
|
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer, file c3457bb1-4744-42df-a89c-d15858b4ad74
|
4
|
|
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial, file e4233f16-cc38-2860-e053-6605fe0a460a
|
4
|
|
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients, file 4e505980-bd6e-40c3-ae5f-f7710eddfe0a
|
3
|
|
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy, file df920d25-96c3-4086-94e2-33b794f9634a
|
3
|
|
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors, file e4233f15-00ab-2860-e053-6605fe0a460a
|
3
|
|
New Targets for Therapy in Pancreatic Cancer, file e4233f15-00ac-2860-e053-6605fe0a460a
|
3
|
|
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction, file e4233f16-2340-2860-e053-6605fe0a460a
|
3
|
|
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience, file e4233f17-03d7-2860-e053-6605fe0a460a
|
3
|
|
null, file 7aac849c-2fda-48fd-a316-da3cd16bf4c0
|
2
|
|
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy, file 9ad61e64-d902-4872-8bb9-b41c01c9fb6b
|
2
|
|
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides., file e4233f14-edfc-2860-e053-6605fe0a460a
|
2
|
|
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer, file e4233f15-6e57-2860-e053-6605fe0a460a
|
2
|
|
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation, file e4233f17-6ad0-2860-e053-6605fe0a460a
|
2
|
|
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events, file e4233f17-8ede-2860-e053-6605fe0a460a
|
2
|
|
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study, file e4233f18-601c-2860-e053-6605fe0a460a
|
2
|
|
Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study, file e4233f18-9188-2860-e053-6605fe0a460a
|
2
|
|
null, file e4233f18-bf77-2860-e053-6605fe0a460a
|
2
|
|
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50, file e4233f18-c690-2860-e053-6605fe0a460a
|
2
|
|
The Effect of the COVID-19 Lockdown on Melanoma Diagnosis in Italy, file e4233f18-fd29-2860-e053-6605fe0a460a
|
2
|
|
Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup, file a2d48118-14f8-4321-b0c9-89bfdc2992f4
|
1
|
|
Safety of Extended interval Dosing Immune Checkpoint Inhibitors: a multicentre cohort study, file cb2f5460-9013-42c1-b824-d3af99d9463b
|
1
|
|
Epirubicin plus low-dose trastuzumab in HER2 positivemetastatic breast cancer, file e4233f15-013d-2860-e053-6605fe0a460a
|
1
|
|
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy(HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis ofovarian origin, file e4233f15-0140-2860-e053-6605fe0a460a
|
1
|
|
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice., file e4233f15-0176-2860-e053-6605fe0a460a
|
1
|
|
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study, file e4233f17-6224-2860-e053-6605fe0a460a
|
1
|
|
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis, file e4233f17-d999-2860-e053-6605fe0a460a
|
1
|
|
Outcomes of systemic targeted therapy in recurrent RCC Renal Cell Carcinoma treated with adjuvant sunitinib, file e4233f18-69e8-2860-e053-6605fe0a460a
|
1
|
|
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation, file e4233f18-7b1d-2860-e053-6605fe0a460a
|
1
|
| Totale |
2.384 |